Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2023-10-23 Governance Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
2023 Corporate Governance Statement and Appendix 4G 37 pages 969.9KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement and Appendix 4G' for the year ended 30 June 2023. It discusses the company's corporate governance practices, board responsibilities, diversity policy, and compliance with ASX Corporate Governance Council Principles and Recommendations. The content focuses on governance structures, board composition, and policies rather than financial results or operational performance. There is no indication that this is an Annual Report, Audit Report, or any financial statement. The document is a detailed governance report, consistent with the definition of Governance Information (CGR). The length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is Governance Information (CGR).
2023-10-23 English
Notice of Annual General Meeting/Proxy Form 21 pages 985.4KB
AGM Information Classification · 100% confidence The document is a detailed notice and explanatory memorandum for the 2023 Annual General Meeting (AGM) of PYC Therapeutics Limited. It includes the date, location, agenda items such as the Annual Report presentation, resolutions for shareholder voting including the Remuneration Report, director re-election, and other governance matters. It also provides proxy voting instructions and legal compliance information related to the AGM. The document does not contain the actual Annual Report or financial statements but refers shareholders to the Annual Report available on the company's website. This is a typical AGM notice and proxy solicitation document, not the Annual Report itself or any other financial report. Therefore, the correct classification is AGM Information (AGM-R).
2023-10-23 English
PYC Presenting on PYC-001 Program at OTS 2023 Meeting 2 pages 239.5KB
Investor Presentation Classification · 90% confidence The document is an announcement dated 20 October 2023 from PYC Therapeutics about an upcoming poster presentation at the Oligonucleotide Therapeutics Society 2023 Annual Meeting. It highlights preclinical data and the progression of a drug candidate into human trials. The text does not contain financial statements, earnings data, regulatory certifications, or detailed management discussion. It is a corporate announcement about a scientific presentation and drug development progress, not a financial report or regulatory filing. The document length is 4313 characters, which is relatively short and focused on a specific event. There is no indication of it being a report publication announcement or a regulatory filing. The content fits best under Investor Presentation (IP) as it provides detailed information for investors about the company's drug development progress and upcoming presentation at a scientific meeting, which is typical for investor communications focusing on strategy and pipeline updates.
2023-10-19 English
Notification regarding unquoted securities - PYC 7 pages 32.0KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from PYC Therapeutics Limited dated October 16, 2023, regarding the issue of new unlisted options under an employee incentive scheme. It details the number and type of securities issued, exercise price, expiry date, and references the company's long term incentive plan. The document is a notification of a securities issue, specifically unlisted options, and does not contain financial statements or management discussion. It is not a full financial report, earnings release, or management report. It fits the category of Capital/Financing Update (CAP) as it relates to the issuance of new securities and changes in capital structure.
2023-10-15 English
Investor Presentation ADOA Program 17 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is an investor update presentation dated 5 October 2023 from PYC Therapeutics Limited. It provides detailed information about the company's drug candidate PYC-001 for Autosomal Dominant Optic Atrophy (ADOA), including scientific background, non-clinical data, patient-derived model results, and plans for clinical trials. The content is structured as a presentation with slides, figures, and explanatory notes aimed at investors. There is no indication that this is a full financial report, audit report, or regulatory filing. It is not a transcript of a call, nor an announcement of voting results or dividends. The document is clearly a detailed investor presentation focusing on the drug development program, clinical progress, and scientific rationale. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (8888 characters) and content support this classification with high confidence.
2023-10-04 English
PYC-001 Effective In Both NHPs and Patient-Derived Models 6 pages 512.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 4 October 2023 from PYC Therapeutics about successful preclinical study results of their second drug candidate for Autosomal Dominant Optic Atrophy (ADOA). It details efficacy and safety data from non-human primate studies and patient-derived models, discusses next steps including an Investigational New Drug (IND) application planned for 2024, and invites investors to a webinar. The document is a corporate announcement focused on drug development progress and investor communication, not a financial report, regulatory filing, or detailed management discussion. It does not contain financial statements or quarterly/annual results, nor is it a regulatory compliance document or a proxy solicitation. It is a typical capital/financing update or corporate progress announcement related to drug development and upcoming clinical trial plans. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-10-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.